

Market Announcement

15 March 2023

Neurotech International Limited (ASX: NTI) – Trading Halt

Description

The securities of Neurotech International Limited ('NTI') will be placed in trading halt at the request of NTI, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 17 March 2023 or when the announcement is released to the market.

Issued by

Scarlette de Lavaine

Adviser, Listings Compliance (Perth)

15 March 2023

Sean Maloney
Adviser, Listing Compliance (Perth)
Australian Securities Exchange
Level 40, Central Park
152 St Georges Terrace
Perth WA 6000

BY EMAIL: tradinghaltsperth@asx.com.au

Dear Sean Maloney

Request for Trading Halt

Neurotech International Limited (ASX: NTI) ('Company') requests a trading halt be placed on the Company's securities pursuant to ASX Listing Rule 17.1, pending the release of the final 54 week safety and efficacy data from its phase I/II clinical trial in autism spectrum disorder.

The Company requests the securities remain in halt until the earlier of the release of announcements regarding the above, or the commencement of trade on Friday, 17 March 2023.

The Company is not aware of any reason why the trading halt should not be granted.

This request has been authorised by the Board of Neurotech International Limited.

Yours Faithfully,



Erlyn Dawson
Company Secretary